Oral contraceptives and lipids and lipoproteins: Part I-variations in mean levels by oral contraceptive type

Ronald T. Burkman, Howard A Zacur, Allyn W. Kimball, Peter Kwiterovich, William R. Bell

Research output: Contribution to journalArticle


A randomized clinical trial of oral contraceptives evaluated 67 women on 50 ug ethinyl estradiol (EE) and 1.0 mg norethindrone (NE), 61 women on 35 ug EE and 1.0 mg NE, and 64 women on 35 ug EE and 0.5 mg NE. Fasting lipids and lipoproteins were measured at baseline, three, six and nine months. All groups showed an increase in plasma total cholesterol, triglycerides, low-density lipoprotein/apolipoprotein B and apolipoprotein A-1. The group taking the preparation with 0.5 mg of NE was the only one to result in an elevation of high-density lipoprotein cholesterol; the other two groups showed declines in the mean levels of this lipoprotein over the study time period. Mean changes in lipid/lipoprotein levels associated with oral contraceptive use appear to be at least partially related to the doses of the contraceptive steroids.

Original languageEnglish (US)
Pages (from-to)553-561
Number of pages9
Issue number5
Publication statusPublished - 1989


ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this